MannKind | MNKD - Eigenkapital Und Reserven





Eigenkapital Und Reserven Veränderung Datum
Adma Biologics USD 390.32M 86.99M 2026-03
BioCryst Pharmaceuticals USD -553.84M 434.69M 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Halozyme Therapeutics USD 219.64M 170.82M 2026-03
Insmed USD 704.85M 34.12M 2026-03
Karyopharm Therapeutics USD -292.93M 23.67M 2025-12
MacroGenics USD 21.2M 34.39M 2026-03
MannKind USD -59.2M 8.17M 2026-03
Merck USD 45.88B 6.73B 2026-03
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Novavax USD -144.76M 17.01M 2026-03
Novo Nordisk DKK 26.56B 111.98B 2025-06
Pfizer USD 90.1B 3.63B 2026-03
Sanofi EUR 72.81B 1.1B 2026-03
Xencor USD 515.63M 119.95M 2026-03